<DOC>
	<DOCNO>NCT01227707</DOCNO>
	<brief_summary>This open-label study ass efficacy safety Avastin ( bevacizumab ) plus Xeloda ( capecitabine ) combination standard technique radiotherapy pelvic region neo-adjuvant setting patient locally advance primary rectal cancer . Patients receive 4 course Avastin dose 5 mg/kg intravenously ( iv ) every 2 week 38 day Xeloda dose 825 mg/kg twice daily orally , plus radiation therapy . After surgery , adjuvant treatment 5-fluorouracil/leucovorin , discretion investigator , Avastin 5 mg/kg iv every 2 week least 6 month give .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Plus Xeloda ( Capecitabine ) Patients With Locally Advanced Rectal Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Adult patient , &gt; =18 year age Patients confirm rectal cancer subject surgery would benefit preoperative combine chemoradiotherapy Measurable and/or evaluable lesion accord RECIST criterion EOCG performance status 01 Prior radiotherapy chemotherapy rectal cancer Untreated brain metastasis spinal cord compression primary brain tumor Chronic daily treatment highdose aspirin ( &gt; 325 mg/day ) medication know predispose gastrointestinal ulceration Coexisting malignancy , malignancy diagnose within last 5 year , exception basal squamous cell cancer , cervical cancer situ .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>